By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials.
TORONTO (PRWEB) November 23, 2020
In immuno-oncology research, biomarkers present the opportunity to identify and target the patient response to a potential new therapeutic, but how can it be integrated into a clinical development plan to increase the effectiveness of clinical trials?
With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials.
Join expert speakers from Cerba Research, Amanda Finan Ph.D., Head of R&D IHC; and Eitan Akirav Ph.D., VP, BD, Global Lead – Biomarkers, in a live webinar on Tuesday, December 1, 2020 at 10am EST (3pm GMT/UK).
For more information, or to register for this event, visit A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.